Indamide

Quick links to important sections

Indamide

Treatment option: Hypertension

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Indamide

Quick Facts

Property Description
Active ingredient Indapamide (INN)
Form Tablet (Immediate and Sustained Release)
Pharmacological class Thiazide-like diuretic
Common use Management of High Blood Pressure (Hypertension)
Origin Synthetic compound (Sulfonamide derivative)

What Type of Medicine is Indamide?

Indamide is the trade name for the pharmaceutical agent whose active ingredient is Indapamide (INN), a prescription-only, synthetic compound used primarily as a thiazide-like diuretic and antihypertensive agent. This single-ingredient medicine is chemically classified as a sulfonamide derivative, possessing a unique structure that supports its role in managing cardiovascular health.

Indapamide belongs to the thiazide-like diuretic pharmacological class, which works by acting on the kidneys to promote the removal of sodium (salt) and water from the body into the urine. This classification is distinct from traditional thiazide diuretics because Indapamide also exhibits significant, direct vasodilatory properties that help the walls of the small arteries relax. The dual mechanism is a key feature of its therapeutic profile. The primary general purpose of this agent is to help control high blood pressure (hypertension) and address conditions associated with excessive fluid retention or edema.


Composition and Physical Form of Indapamide

As a synthetic compound, Indapamide is administered exclusively via the oral route and is formulated as a tablet using solid pharmaceutical excipients. The tablets are commonly available in two types: a conventional immediate release formulation, and a modified/sustained release (SR) form. The sustained release tablet is engineered to deliver the active ingredient slowly and consistently over 24 hours. The sustained release formulation is designed for blood pressure control, and its availability allows for a once-daily dosing regimen.

Regulatory References

  1. Flutensif 1.5 mg/5 mg and 1.5 mg/10 mg modified-release tablets - Public Assessment Report (NL MEB)

What side effects are possible with Indamide?

The safety profile of Indamide (Indapamide) is categorized by government regulatory agencies based on frequency and affected body system, strictly defining potential adverse reactions and safety restrictions.

Adverse Reaction Scope

Category Regulatory Summary
Key Adverse Reactions Fluid and electrolyte imbalances (e.g., Hypokalemia, Hyponatremia), metabolic changes (Hyperglycemia, Hyperuricemia), and neurological effects (Headache, Dizziness).
Frequency Classification Common (ge 1/100) effects include Hypokalemia, Headache, Dizziness, and Fatigue. Very Rare (< 1/10,000) serious events include Pancreatitis, Agranulocytosis, and severe skin reactions (SJS/TEN).
System-Organ Classes Effects are officially listed across Metabolism and Nutrition, Nervous System, Gastrointestinal, Skin and Subcutaneous Tissue, Ocular, and Blood and Lymphatic Systems.
Serious Adverse Reactions Officially documented severe risks include life-threatening severe Hyponatremia and Hypokalemia, which may lead to serious cardiac arrhythmias such as Torsade de pointes. Acute ocular effects, including Acute Angle-Closure Glaucoma, are also documented as serious possibilities.

Population-Specific Safety and Restrictions

Safety notes are explicitly documented for certain patient groups. Older adults are noted to have a higher risk of developing severe hyponatremia. The medication is officially contraindicated in cases of Anuria (absence of urine), severe Hepatic Impairment (due to risk of hepatic coma), known Hypersensitivity to sulfonamide derivatives, and pre-existing Hypokalemia. Safety and efficacy have not been established in the pediatric population.

Exposure-Related Patterns

Adverse reactions such as dizziness and orthostatic hypotension are officially noted as more likely to occur at the initiation of treatment. Acute ocular events (glaucoma, myopia) typically manifest within hours to weeks of drug initiation.


Regulatory safety summary: The safety profile is primarily defined by the requirement for periodic monitoring of serum electrolytes (sodium and potassium) and metabolic parameters (glucose and uric acid). This structure, mandated by official regulatory sources, delineates the spectrum of risk from common, expected fluid/metabolic shifts to rare, serious adverse events requiring specific cautions in vulnerable populations.

Overdose and Emergency Response

Overdose Manifestations and Severe Outcomes

Overdose of Indamide is primarily documented as causing pronounced disturbances in fluid and electrolyte balance, leading to the regulatory findings of severe hypotension (excessively low blood pressure) and systemic dehydration. Clinical manifestations often include nausea, vomiting, dizziness, and mental confusion, along with excessive sleepiness (somnolence).

The most severe documented outcomes arise from critical electrolyte shifts, specifically Hypokalemia and Hyponatremia. These imbalances increase the risk for life-threatening cardiac dysrhythmias, including the potential for Torsade de pointes. Additionally, overdose may result in renal failure progression, observed as oliguria advancing to anuria. Patients with pre-existing impaired hepatic function are noted as being at risk for the precipitation of hepatic encephalopathy.

When to Seek Urgent Medical Help

Regulatory agencies mandate that emergency medical attention must be sought immediately in cases of suspected overdose. Urgent contact with emergency services is specifically required if the affected individual presents with signs of severe compromise, such as collapse, a seizure, trouble breathing, or if they cannot be awakened.

As no specific antidote is known, official management focuses on symptomatic and supportive treatment, including measures such as gastric lavage or activated charcoal to remove the drug, and continuous hospital monitoring to restore fluid and electrolyte balance.

Therapeutic Uses of Indamide

What Indamide Treats: Main Uses and Benefits

The primary therapeutic applications of this medication are applied in addressing chronic cardiovascular risk and symptomatic fluid disorders. Its clinical applications generally fall into two distinct, yet often related, areas: the sustained management of systemic hypertension (High Blood Pressure) and the treatment of excessive fluid and salt accumulation (Edema).

Therapeutic Benefits

Indapamide is commonly used for the sustained control of elevated vascular pressure. This ongoing management may assist with reducing the patient's risk of developing symptoms related to organ-specific functional stress over time, particularly for individuals with mild-to-moderate hypertension.

It is also applied in conditions presenting with systemic or localized discomfort related to fluid retention. By managing symptoms related to this excess fluid, the medication may provide supportive relief that helps ease the overall symptom burden of physical discomfort from swelling. For instance, in patients with Congestive Heart Failure, this benefit supports the patient during difficult episodes.

“This medication is considered relevant for managing symptoms related to systemic imbalance and provides support that helps ease the overall symptom load.”

Quick Fact: Relief for Edema
Primary Symptom Relieved Swelling and physical discomfort related to fluid retention
Main Therapeutic Goal Long-term Cardiovascular Protection
Typical Use For patients with Mild-to-Moderate Hypertension

Regulatory References

  1. NIH MedlinePlus Drug Information on Indapamide

Eligibility and Restrictions for Use

Who Can and Cannot Use Indamide?

The official eligibility for Indamide is strictly defined by specific organ function, hypersensitivity status, and physiological factors, as outlined in government regulatory documents.

Absolute Contraindications Indamide must not be used in populations with Anuria (absence of urine production) or a known hypersensitivity to Indapamide or any sulfonamide-derived drugs. Use is also strictly prohibited in patients with severe renal failure (creatinine clearance below 30 mL/min), severe hepatic impairment (including hepatic encephalopathy), or pre-existing hypokalaemia (low blood potassium).

Age and Reproductive Status The medication is approved for use in adults but is not recommended for the pediatric population (children and adolescents) due to a lack of established safety and efficacy data. Older adults may use the medicine when renal function is normal or minimally impaired, but require special caution and monitoring. Furthermore, Indamide is not normally taken by pregnant women and is not recommended for breastfeeding mothers, who must discontinue nursing or the medication.

Conditional Use Status Restrictions apply to patients with moderate renal impairment or non-severe hepatic impairment, where use requires careful monitoring. Caution is also advised in patients with conditions such as gout, Systemic Lupus Erythematosus (SLE), or pre-existing electrolyte imbalances.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Indapamide identifies several interactions based on effects on electrolyte balance and blood pressure control.

Contraindicated Combinations

Combination Official Interaction
Lithium Reduced renal clearance, leading to high risk of Lithium toxicity.
Torsades de pointes-Inducing Drugs (e.g., Class Ia/III Antiarrhythmics) Increased risk of severe ventricular arrhythmias (Torsades de pointes) due to additive hypokalaemia.
Aliskiren Contraindicated in patients with Diabetes due to increased renal and hypotensive risk.

Pharmacodynamic Interactions

  • ACE Inhibitors/ARBs: Risk of sudden hypotension and/or acute renal failure when co-initiated, particularly with pre-existing sodium depletion.
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Possible reduction in the anti-hypertensive effect and risk of acute renal failure in dehydrated patients.
  • Potassium-Lowering Compounds: Increased risk of hypokalaemia due to an additive electrolyte effect (e.g., Corticosteroids, Amphotericin B).
  • Digitalis Preparations: Hypokalaemia can predispose the heart to the toxic effects of digitalis (cardiac glycosides).

Administration Restrictions

  • Timing: The diuretic may need to be stopped 3 days prior to initiating an ACE Inhibitor to mitigate risk of sudden hypotension.
  • Substance Interference: High-Sodium Products (e.g., certain antacids) are documented to reduce the anti-hypertensive efficacy of Indapamide.

Population-Specific Notes

  • Impaired Hepatic Function: Minor electrolyte changes are documented to precipitate hepatic encephalopathy; immediate cessation of the diuretic is required if this occurs.
  • Metformin: Co-administration is restricted when plasma creatinine exceeds regulatory thresholds due to the risk of lactic acidosis.

Mechanism of Action

Dual Mechanism: The Renal and Vascular Approach

Indapamide utilizes a dual mechanism of action by simultaneously influencing fluid volume and arterial resistance, which contributes to its overall physiological response. This targeted action engages core mechanisms that regulate pathways in both the kidney and the circulatory system.


Modulation of Renal Electrolyte Transport

The primary renal action involves the inhibition of the Sodium-Chloride Cotransporter ( Na^+/ Cl^- symporter) located in the distal convoluted tubule of the kidney. By blocking this transporter, the drug reduces the reabsorption of salt and chloride ions, initiating a mechanistic cascade that promotes the osmotic excretion of water. This action results in a reduction of intravascular fluid volume (Preload), influencing systemic hemodynamic load.


Direct Arterial Smooth Muscle Modulation

A separate, critical mechanism involves the direct modulation of calcium ion ( Ca^2+) flux within the vascular smooth muscle cells of the small arteries. This action suppresses the internal Ca^2+ signals necessary for contraction, causing the vessel walls to relax and widen (vasodilation). This suppression of vessel tone significantly lowers the Total Peripheral Resistance (Afterload), thereby reducing arterial load.


Unified Causal Cascade

The combined mechanism provides a dual influence on volume and resistance pathways. This dual physiological action results in a sustained influence on the pressure exerted on arterial walls. The vascular effect, in particular, is maintained even at doses where the diuretic effect is minimal, maintaining a reduced mean arterial pressure without proportionally increasing urinary volume.

Dosage and Administration Information

How to Use Indamide: Administration Guidelines

This section outlines the standardized administration and dosing instructions for Indapamide.


Administration Scope

Instruction Detail
Route of administration: Oral use only.
Dosing schedule (Hypertension): Initial dose is 1.25 mg (IR) or 1.5 mg (PR) once daily. For the IR form, the maximum daily dose is 5 mg. The PR dose remains fixed at 1.5 mg once daily.
Dosing schedule (Edema): Initial dose is 2.5 mg (IR) once daily, with a maximum of 5 mg once daily.
Timing in relation to meals: May be taken with or without food.
Age-group administration rules: Older Adults: Cautious dose selection, typically starting at the low end of the range. Pediatric: Safety and effectiveness are not established in patients under 18 years.
Missed-dose rules: Skip the missed dose if it is almost time for the next dose; do not double doses.
Special procedural conditions: Prolonged-Release tablets must be swallowed whole with water and must not be chewed or crushed.

Instruction Classifications (High-Level)

The medicine is designated for oral use with a once daily frequency pattern. Dose titration for the Immediate-Release formulation may occur at intervals of four weeks if the response to therapy is inadequate. The drug should be taken in the morning.


Connection to the Overall Use Protocol

The administration follows a simple, single-dose, morning regimen to standardize use and provide consistent delivery of the medicine. These rules, which include the requirement to swallow PR tablets whole, protect the pharmaceutical structure intended for slow release. The slow titration period for the IR form ensures a deliberate process for establishing the individual's long-term maintenance dose.

Recent Clinical Evidence

Research evidence / Overview of Studies for Indamide

Evidence for Use in Managing High Blood Pressure (Hypertension)

The research foundation for Indamide is characterized by large-scale Randomized Controlled Trials (RCTs) and systematic reviews. Regulators and researchers note that these studies were designed to establish how Indamide was studied for managing elevated blood pressure and tracking outcomes such as the incidence of stroke and heart attack.

Studies conducted for this purpose examined whether treatment regimens that included Indamide were associated with changes in serious cardiovascular events. Findings from these large trials described patterns where the observed populations reported a lower incidence of events like stroke and heart attack, along with observed differences in all-cause mortality, when compared to a placebo. Research so far describes patterns where blood pressure measurements remained consistent across the defined study periods.


Evidence for Use in Treating Excessive Fluid Retention (Edema)

This section will describe the clinical trials and regulatory findings that evaluated Indamide in the context of fluid and salt accumulation associated with conditions like congestive heart failure. The studies monitored outcomes related to patient-reported outcomes describing perceived discomfort and tracked changes in body weight measurements.

Clinical trials and regulatory documents describe that Indamide was observed in the management of systemic fluid accumulation. The depth of the evidence base here is limited. The body of evidence for edema is not as extensive as the research available for cardiovascular outcomes.


Evidence in Special Populations

Research has been conducted in distinct patient groups, such as the very elderly (patients aged 80 years) and individuals with co-existing conditions like Type 2 Diabetes Mellitus, to understand how evidence was evaluated in these populations.

A key research effort was evaluated in the very elderly. Findings from this trial indicated that treatment initiation in this age group described patterns related to a lower reported incidence of stroke and death in the observed groups.


Gaps and Uncertainties in Existing Research

The current research base may be limited in certain areas. For instance, the modified or sustained-release (SR) formulation was observed in some studies to have different patterns compared to the immediate-release (IR) form in non-randomized analyses. These findings are preliminary and data are still emerging, which, according to researchers, requires dedicated prospective trials. Furthermore, research is ongoing to further explore some of the physiological effects observed in studies.

Key Studies & References

  1. Treatment of hypertension in patients 80 years and older: Hypertension in the Very Elderly Trial (HYVET) randomized trial data
  2. National Institutes of Health (NIH) MedlinePlus Drug Information: Indapamide

Frequently Asked Questions (FAQ)

Common questions about Indamide (FAQ)

Q: What is the difference between Indamide and other 'water pills'?

Official documents describe Indamide as a thiazide-like diuretic with a unique dual mechanism of action. This means it works both in the kidneys, like a typical water pill, and directly on the blood vessel walls to help them relax. This extra effect of reducing blood vessel resistance is how it helps lower blood pressure.


Q: Are there any long-term effects of taking Indamide every day?

Indamide is generally prescribed as a long-term treatment for conditions like high blood pressure. Because it affects how your body handles fluids and minerals, official safety requirements mandate periodic monitoring of blood tests, including potassium, sodium, glucose, and uric acid. This monitoring helps manage potential long-term metabolic changes.


Q: Do side effects from Indamide often lessen or disappear over time?

According to official product information, most adverse effects are mild and transient or tend to stabilize once treatment is consistent. Effects like dizziness and feeling lightheaded are specifically noted as being more likely to occur when you first start taking the medicine.


Q: Are there any specific foods or diet restrictions necessary while on Indamide?

Regulatory documents suggest that a strict low-salt diet is not generally recommended alongside Indamide, as the medicine itself can cause low sodium levels. Information on use describes a connection between managing weight and monitoring food content, especially high sodium or potassium foods.


Q: How is Indamide different from other common diuretics like Hydrochlorothiazide (HCTZ)?

Indamide is classified as thiazide-like but is differentiated by its direct vascular effect on blood vessel walls. This means it helps lower blood pressure not only by increasing urination, but also by relaxing the small arteries, which is a distinguishing feature from traditional thiazides.


Q: What is the purpose of the different strengths Indamide comes in?

Different strengths, such as the 1.25 mg and 2.5 mg immediate-release tablets, are made available to allow for dose adjustment (titration) over time. This structure supports its use in different conditions, like fluid retention or high blood pressure, at the lowest possible effective dose.


Q: How long do common side effects from Indamide usually last?

While official product information does not specify the exact time frame for resolution, most common adverse effects are classified as transient (short-lived). These effects may resolve as the body adjusts to the medication over the first few weeks of therapy.


Q: Does Indamide interact with supplements such as magnesium or calcium?

Official warnings indicate that Indamide is known to increase the loss of magnesium through urine, which may result in low magnesium levels. It may also be associated with a slight and temporary increase in calcium levels in the blood.


Q: Is it safe to consume alcohol while taking Indamide?

Regulatory information notes that consuming alcohol while using Indamide may have additive effects in lowering blood pressure. This may increase the potential for orthostatic hypotension, which is a feeling of dizziness or lightheadedness when standing up quickly.


Q: How quickly does Indamide typically start working after the first dose?

The diuretic effect (increased urination) of Indamide may start quickly, typically within 1 to 2 hours after the first dose. However, the full blood pressure lowering effect usually takes longer, often needing 1 to 2 weeks of regular use to reach its full therapeutic effect.


Q: What is the usual recommended period of time people stay on Indamide?

According to official information, Indamide is usually taken for a long time to manage chronic conditions like high blood pressure. In many cases, treatment continuation is described as being for the long term to help maintain blood pressure control.


Q: What happens to the body when someone suddenly stops taking Indamide?

Regulatory documents state there is no evidence of rebound hypertension (a sudden, sharp rise in blood pressure) upon the withdrawal of Indamide. However, stopping any medication prescribed for blood pressure may cause the blood pressure to increase.


Q: Does Indamide cause photosensitivity or increased sun sensitivity?

Official warnings state that photosensitivity reactions (increased sensitivity to sunlight) have been reported with this class of diuretics. If such a reaction occurs, regulatory documents note that discontinuation of treatment has been recommended if a reaction occurs.

How should Indamide be stored and disposed of?

How to Store and Dispose of Indapamide

Indapamide tablets must be stored at Controlled Room Temperature, which is generally maintained between 20 and 25 C (68 and 77 F). The medicine must be kept from freezing and stored away from excessive heat and moisture.

Storage and Protection

The product must be kept in the original container and maintained tightly closed to protect its integrity. A key requirement is to store Indapamide out of the sight and reach of children to prevent accidental ingestion.

Disposal Requirements

Regulatory guidelines instruct that unused or expired tablets must not be flushed down a toilet or sink drain. If a drug take-back program is unavailable, the medicine should be disposed of in household trash by mixing it with an undesirable substance (such as dirt or used coffee grounds) and sealing the mixture in a container before discarding it, as per federal recommendations. All identifying information must be removed from the container prior to disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Indamide found in:

A-Z Index: